C-Terminal Provasopressin (Copeptin) as a Novel and Prognostic Marker in Acute Myocardial Infarction: Leicester Acute Myocardial Infarction Peptide (LAMP) Study

Background— The role of the vasopressin system after acute myocardial infarction is unclear. Copeptin, the C-terminal part of the vasopressin prohormone, is secreted stoichiometrically with vasopressin. We compared the prognostic value of copeptin and an established marker, N-terminal pro-B-type natriuretic peptide (NTproBNP), after acute myocardial infarction. Methods and Results— In this prospective single-hospital study, we recruited 980 consecutive post–acute myocardial infarction patients (718 men, median [range] age 66 [24 to 95] years), with follow-up over 342 (range 0 to 764) days. Plasma copeptin was highest on admission (n=132, P<0.001, day 1 versus days 2 to 5) and reached a plateau at days 3 to 5. In the 980 patients, copeptin (measured at days 3 to 5) was elevated in patients who died (n=101) or were readmitted with heart failure (n=49) compared with survivors (median [range] 18.5 [0.6 to 441.0] versus 6.5 [0.3 to 267.0] pmol/L, P<0.0005). With logistic regression analysis, copeptin (odds ratio, 4.14, P<0.0005) and NTproBNP (odds ratio, 2.26, P<0.003) were significant independent predictors of death or heart failure at 60 days. The area under the receiver operating characteristic curves for copeptin (0.75) and NTproBNP (0.76) were similar. The logistic model with both markers yielded a larger area under the curve (0.84) than for NTproBNP (P<0.013) or copeptin (P<0.003) alone, respectively. Cox modeling predicted death or heart failure with both biomarkers (log copeptin [hazard ratio, 2.33], log NTproBNP [hazard ratio, 2.70]). In patients stratified by NTproBNP (above the median of ≈900 pmol/L), copeptin above the median (≈7 pmol/L) was associated with poorer outcome (P<0.0005). Findings were similar for death and heart failure as individual end points. Conclusions— The vasopressin system is activated after acute myocardial infarction. Copeptin may predict adverse outcome, especially in those with an elevated NTproBNP (more than ≈900 pmol/L).

[1]  G. Navis,et al.  Drawbacks and Prognostic Value of Formulas Estimating Renal Function in Patients With Chronic Heart Failure and Systolic Dysfunction , 2006, Circulation.

[2]  C. Bieglmayer,et al.  Parathyroid hormone monitoring during total parathyroidectomy for renal hyperparathyroidism: pilot study of the impact of renal function and assay specificity. , 2006, Clinical chemistry.

[3]  W. Abraham,et al.  Aquaretic effect of lixivaptan, an oral, non-peptide, selective V2 receptor vasopressin antagonist, in New York Heart Association functional class II and III chronic heart failure patients. , 2006, Journal of the American College of Cardiology.

[4]  J. Struck,et al.  Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin. , 2006, Clinical chemistry.

[5]  J. Struck,et al.  Copeptin, a stable peptide derived from the vasopressin precursor, is elevated in serum of sepsis patients , 2005, Peptides.

[6]  R. Pizov.  A Comparison of Vasopressin and Epinephrine for Out-of-Hospital Cardiopulmonary Resuscitation , 2004 .

[7]  I. Squire,et al.  N-terminal pro-atrial natriuretic peptide (N-ANP) and N-terminal pro-B-type natriuretic peptide (N-BNP) in the prediction of death and heart failure in unselected patients following acute myocardial infarction. , 2004, Clinical science.

[8]  C. O'connor,et al.  Effects of Tolvaptan, a Vasopressin Antagonist, in Patients Hospitalized with Worsening Heart Failure: A Randomized Controlled Trial , 2004 .

[9]  H. Sitter,et al.  A comparison of vasopressin and epinephrine for out-of-hospital cardiopulmonary resuscitation. , 2004, The New England journal of medicine.

[10]  K. Kikuchi,et al.  Arginine vasopressin increases the rate of protein synthesis in isolated perfused adult rat heart via the V1 receptor , 1999, Molecular and Cellular Biochemistry.

[11]  J. Burbach,et al.  Structure–Function Relationships of the Vasopressin Prohormone Domains , 1998, Cellular and Molecular Neurobiology.

[12]  M. Gheorghiade,et al.  ACUTE AND CHRONIC THERAPEUTIC IMPACT OF A VASOPRESSIN ANTAGONIST IN CONGESTIVE HEART FAILURE (ACTIV IN CHF) INVESTIGATORS. EFFECTS OF TOLVAPTAN, A VASOPRESSIN ANTAGONIST, IN PATIENTS HOSPITALIZED WITH WORSENING HEART FAILURE: A RANDOMIZED CONTROLLED TRIAL , 2004 .

[13]  K. Khunti,et al.  Identification of previously undiagnosed left ventricular systolic dysfunction: community screening using natriuretic peptides and electrocardiography , 2003, European journal of heart failure.

[14]  M. Dünser,et al.  Arginine Vasopressin in Advanced Vasodilatory Shock: A Prospective, Randomized, Controlled Study , 2003, Circulation.

[15]  J. Herlitz,et al.  N-Terminal Pro-B-Type Natriuretic Peptide and Long-Term Mortality in Acute Coronary Syndromes , 2002, Circulation.

[16]  G. S. Ranger,et al.  THE PHYSIOLOGY AND EMERGING ROLES OF ANTIDIURETIC HORMONE , 2002, International Journal of Clinical Practice.

[17]  Nader Rifai,et al.  Multimarker Approach to Risk Stratification in Non-ST Elevation Acute Coronary Syndromes: Simultaneous Assessment of Troponin I, C-Reactive Protein, and B-Type Natriuretic Peptide , 2002, Circulation.

[18]  E. Antman,et al.  Prognostic value of N-terminal pro-atrial and pro-brain natriuretic peptide in patients with acute coronary syndromes. , 2002, The American journal of cardiology.

[19]  G. Singh Ranger.  The physiology and emerging roles of antidiuretic hormone. , 2002, International journal of clinical practice.

[20]  Hugo A. Katus,et al.  Myocardial infarction redefined--a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. , 2000, European heart journal.

[21]  C. Frampton,et al.  Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: new neurohormonal predictors of left ventricular function and prognosis after myocardial infarction. , 1998, Circulation.

[22]  N. Reichek,et al.  Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. , 1989, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[23]  S. Goldsmith,et al.  Vasopressin as vasopressor. , 1987, The American journal of medicine.

[24]  J. Hanley,et al.  A method of comparing the areas under receiver operating characteristic curves derived from the same cases. , 1983, Radiology.

[25]  G. Robertson,et al.  Development and clinical application of a new method for the radioimmunoassay of arginine vasopressin in human plasma. , 1973, The Journal of clinical investigation.

[26]  D. A. Holwerda.  A glycopeptide from the posterior lobe of pig pituitaries. 2. Primary structure. , 1972, European journal of biochemistry.

[27]  D. A. Holwerda.  A glycopeptide from the posterior lobe of pig pituitaries. I. Isolation and characterization. , 1972, European journal of biochemistry.